On June 29, Hengrui Pharma rose 3.02% in regular trading, trading at HKD 55.55/share, with turnover of HKD 109 million. The stock rebounded from a 6.45% decline in the prior session, supported by a broad pharmaceutical sector rally and a string of recent positive regulatory developments.

On the news front, the company recently secured marketing approval for CyclASol, a cyclosporine ophthalmic solution for dry eye disease, breaking a six-year domestic monopoly in the category. Additionally, adebrelimab injection received approval to expand into non-small cell lung cancer neoadjuvant therapy, marking its second approved lung cancer indication. The European Medicines Agency also accepted the marketing application for revulutamide tablets for prostate cancer, representing the company's first self-developed innovative drug submitted for EU approval.

Within the Pharmaceuticals sector, the overall sector posted broad gains. Among individual stocks, ASYMCHEM up 8.63%, CSPC PHARMA up 7.17%, LUYE PHARMA up 5.62%, SBP GROUP up 5.4%, HANSOH PHARMA up 3.77%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)